Tentarix Biotherapeutics is pioneering the development of advanced conditional multi-specific biologics, referred to as Tentacles™, which are designed to enhance therapeutic efficacy while minimizing side effects. Their innovative approach focuses on understanding the cell surface proteome, allowing for precise targeting of specific cells involved in disease. By binding to signaling receptors and other cell markers, Tentarix leverages combinatorial avidity to create multifunctional biologics that can effectively address complex biological challenges. This holistic strategy aims to improve treatment outcomes by ensuring that therapies are tailored to the unique characteristics of the target cells.

The Tentacles™ platform is built on three critical pillars: CellSurf™, HuTARG™, and FunctionSeq™. CellSurf™ focuses on defining key features of cells involved in disease by analyzing cell surface proteomes in both healthy and diseased states. HuTARG™ utilizes a high-throughput mammalian display platform to discover fully human binders from a vast library of unique VH scaffolds, ensuring the generation of diverse and effective therapeutic candidates. FunctionSeq™ emphasizes a function-first approach, enabling the screening of millions of Tentacles to identify optimal agonists with specific activity and cell targeting capabilities. This comprehensive platform positions Tentarix at the forefront of biologic innovation, aiming to deliver intelligent therapies that are both effective and patient-centric.

United States

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage powerful synergistic biology. On an unprecedented scale, we are leading a fundamental change in the methods of discovery and engineering of multi-specific biologics.

https://www.businesswire.com/news/home/20211014005033/en/Tentarix-Biotherapeutics-Emerges-with-50-Million-Series-A

Tentarix Biotherapeutics

Company Details